Monitor the company's progress on its pivotal clinical study and next-generation catheter development. The corporate goals for 2026 may provide insight into future revenue drivers, but no specific financial guidance was provided.
Price Chart
Executive Summary
Pulse Biosciences updated its investor presentation with new details about its pivotal clinical study of the nsPFA Cardiac Catheter for atrial fibrillation, its next-generation nPulse cardiac catheter under development, and its 2026 corporate goals in electrophysiology, cardiac surgery, and soft tissue ablation. This is a routine disclosure of forward-looking information.
Key Facts
- Updated investor presentation posted on April 16, 2026
- Presentation includes new details about the pivotal clinical study of the nsPFA Cardiac Cather for atrial fibrillation
- Presentation includes description of the next-generation nPulse cardiac catheter under development
- Presentation includes summary of 2026 corporate goals in electrophysiology, cardiac surgery, and soft tissue ablation
- Information is forward-looking and subject to risks and uncertainties
Financial Impact
No immediate financial impact disclosed
Risk Factors
- Clinical trial results may not meet expectations
- Development of next-generation catheter may face delays
- Forward-looking statements are subject to risks and uncertainties
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-012498 |
| Document: 0001437749-26-012498-index-headers.html | 0001437749-26-012498 |
| Document: 0001437749-26-012498-index.html | 0001437749-26-012498 |
| Document: 0001437749-26-012498.txt | 0001437749-26-012498 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 8-K | $46.32 | awaiting T+60 | — | $53.02 (+14.46%) |
Oct 7, 2026 19d ago | 8-K | $49.09 | awaiting T+60 | — | $53.02 (+8.01%) |
Sep 15, 2026 5w ago | 8-K | $55.20 | awaiting T+60 | — | $53.02 (−3.95%) |
Aug 6, 2026 11w ago | 8-K | $42.41 | awaiting T+60 | — | $53.02 (−25.02%) |
Aug 6, 2026 11w ago | 424B5 | $42.41 | awaiting T+60 | — | $53.02 (−25.02%) |
Jul 29, 2026 12w ago | 8-K | $34.25 $52.68 | ▲ +53.81% | ▲ +49.08% | $53.02 (+54.80%) |
Jun 12, 2026 19w ago | Institutional Cluster | $24.37 $48.79 | ▲ +100.21% | ▲ +96.94% | $53.02 (+117.56%) |
Jun 10, 2026 19w ago | 8-K | $24.99 $54.71 | ▲ +118.93% | ▲ +112.35% | $53.02 (+112.16%) |
May 15, 2026 23w ago | Insider Cluster | $25.61 $43.32 | ▲ +69.15% | ▲ +64.30% | $53.02 (+107.03%) |
May 11, 2026 24w ago | Insider Cluster | $19.08 $37.90 | ▲ +98.64% | ▲ +94.24% | $53.02 (+177.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers